Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
|
|
Aadi Bioscience, Inc. (ARPO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/11/2021 |
GN
| Aerpio Reports Fourth Quarter and Full Year 2020 Financial Results and Provides Business Update |
| 03/05/2021 |
GN
| Quantum Leap Healthcare Collaborative Discontinues Testing of Aerpio Pharmaceutical's Razuprotafib in I-SPY COVID Trial |
| 01/05/2021 |
GN
| Aerpio Announces Strategic Review after Topline Results from Razuprotafib Glaucoma Phase 2 Trial |
| 11/10/2020 |
GN
| Aerpio Reports Third Quarter 2020 Financial Results and Provides Business Update |
| 10/26/2020 |
GN
| Aerpio Announces First Patient Dosed with Razuprotafib in the Phase 2 Trial for the Prevention and Treatment of ARDS in Patients with Moderate-to-Severe COVID-19 |
| 09/17/2020 |
GN
| Aravive Appoints Michael W. Rogers to Board of Directors |
| 09/15/2020 |
GN
| Aerpio Announces Enrollment Completed in the 28-Day Phase 2 Razuprotafib Glaucoma Trial |
| 09/01/2020 |
GN
| Aerpio and Quantum Leap Announce First Patients Dosed with Razuprotafib in the I-SPY COVID Trial to Treat ARDS in Critically-ill COVID-19 Patients |
| 08/12/2020 |
GN
| Aerpio Reports Second Quarter 2020 Financial Results and Provides Business Update |
| 08/10/2020 |
GN
| Aerpio Pharmaceuticals to Report Second Quarter 2020 Financial Results on August 12 |
| 08/04/2020 |
GN
| Aerpio Pharmaceuticals, Inc. Announces a Second Clinical Trial with Funding from MTEC to Evaluate Razuprotafib for the Prevention and Treatment of ARDS in Patients with Moderate to Severe COVID-19 |
| 06/08/2020 |
GN
| Aerpio Announces Change to Virtual Format for its 2020 Annual Meeting of Stockholders due to COVID-19 |
| 06/08/2020 |
GN
| Aerpio Hosting Key Opinion Leader Call on a Novel Mechanism for the Treatment of Glaucoma |
| 05/27/2020 |
GN
| Aerpio Pharmaceuticals, Inc. and Quantum Leap Healthcare Collaborative Announce the Selection of Razuprotafib for Evaluation in the I-SPY COVID Trial for the Treatment of Acute Respiratory Distress Syndrome in COVID-19 Patients |
| 05/12/2020 |
GN
| Aerpio Announces Amended Licensing Deal with Gossamer Bio on its Inflammatory Bowel Disease (IBD) Product Candidate GB004 (formerly AKB-4924) |
| 05/07/2020 |
GN
| Aerpio Reports First Quarter 2020 Financial Results and Provides Business Update |
| 03/16/2020 |
GN
| Aerpio Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update |
| 03/12/2020 |
GN
| Aerpio Pharmaceuticals to Report Year Ended December 31, 2019 Financial Results on Monday, March 16, 2020 |
| 04/17/2019 |
GN
| Analysis: Positioning to Benefit within Galmed Pharmaceuticals, Liquidia Technologies, Taylor Devices, Kingstone Companies, Aerpio Pharmaceuticals, and Pingtan Marine Enterprise — Research Highlights Growth, Revenue, and Consolidated Results |
| 11/14/2018 |
GN
| Recent Analysis Shows Atlas Financial, Royal Dutch Shell, Vaalco Energy, Myovant Sciences, Aerpio Pharmaceuticals, and Wheeler Real Estate Investment Trust Market Influences — Renewed Outlook, Key Drivers of Growth |
|
|